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European cystic fibrosis society consensus on
standards—a roadmap to bbest careQ1. Remarkable improvement in prognosis
There has been a steady and impressive improvement in
the outlook for people with cystic fibrosis (CF) since the
first clear description of the condition in 1938 [1]. Progress
has been particularly impressive over the last 20 years [2–4].
There are still many who remember the time when CF was a
short-lived tragic disease of early childhood treated, almost
reluctantly, by general paediatricians who knew the inevi-
table outcome—a short-lived miserable existence for the
infant, increasingly distressing to the family. But nowadays
the situation is quite different and the spectrum of the
condition extends from the detection of the carrier state in a
healthy individual, to management of an adult with CF in
the years following a bilateral lung transplant. Virtually
every system in the body is involved at some stage of life
and optimal treatment is wide ranging and complex and
requires the expertise of a large number of health care
professionals.2. General medical advances and more effective
treatment at CF centers
Why has the outlook for people with CF become so
much better? Of course, CF is not the only condition to
have a radically improved outlook e.g. acute lymphoblastic
leukaemia is often compared—a previously fatal disease
now more often than not curable. These and similar
conditions all have in common a vigorous approach to
treatment by specialised teams, who spend much of their
time treating the disease in question. In doing so they gain
increasing experience in the practical management of the
disease and its complications. The availability of new and
better drugs, more efficient methods of delivery and new
complications resulting from extended survival, have all
increased the complexity and knowledge required to
deliver the best available treatment for people with cystic
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advances, most would agree that the improving prognosis
has been largely due to the development, introduction and
evaluation of more effective treatment regimens for the
respiratory, nutritional and other problems, by teams of
professionals working at large specialist CF centers [5–10].3. A new positive attitude to treatment and higher
expectations
Another important factor has been the more positive
attitude on the part of those responsible for treating people
with CF and their reluctance to accept that decline and
premature death were inevitable [7]. The previous hopeless
attitude was by no means unusual and even in 1987 Prof.
Tim David complained that ba passive fatalistic approach to
treatment is a major obstacle to progress and the attitude
that CF is a hopeless incurable disease is all too prevalentQ
[11]. Also the expectations of the patients and families have
increased as the benefits of more aggressive treatment
became apparent.4. The concept of the bpoint of no returnQ
In most people with CF the presence and severity of
chronic pulmonary infection is the major determinant of
their health and survival [12,13]. Observing the progress of
many people with CF over many years reinforces the
concept of there being a bpoint of no returnQ [14], which
coincides with the onset of chronic pulmonary infection.
The distinction between bCF diseaseQ (physicochemical
abnormality within uninfected airways due to absence or
dysfunction of CFTR) and blung diseaseQ (the situation
after the onset of chronic infection and excessive
inflammation) is a useful concept. Once dlung diseaseT is
established, the infection cannot be eradicated and there is
a gradual but relentless deterioration of respiratoryis 4 (2005) 1–5ed by Elsevier B.V. All rights reserved.
Editorial2function, the speed of which is determined mainly by the
intensity of treatment [15].5. Close monitoring and effective treatment must follow
early diagnosis
It has become apparent that the progressive deterioration
of respiratory function described in the older CF literature is
not inevitable. If respiratory infection is identified early and
eradicated by appropriate antibiotic treatment, chronic
infection can be prevented or certainly delayed for many
years [15–18]. Also the early malnutrition and later growth
problems can be avoided when enzyme and nutritional
intervention is started soon after birth [19]. To achieve this
for all infants with CF, neonatal screening followed by early
diagnosis, close monitoring and effective treatment is
mandatory. The CF multidisciplinary teams have a respon-
sibility to undertake clinical audit and research in a condition,
such as CF, where treatment is continually improving,
changing and becoming increasingly more effective. In
practice these are more easily accomplished at CF centers
where many patients are treated—useful CF clinical research
from small clinics at local hospitals is virtually non-existent
due to lack of patients, time and expertise. At the CF center
general policy and the management of individual patients are
discussed at weekly team meetings and ward rounds.
Experience gained from treating many people with CF is
shared first between team members and colleagues in related
specialities and subsequently between colleagues in other
centers and at international meetings.
The results must be assessed in the long term for
although pulmonary damage, sustained before the diagnosis
is made or as a result of suboptimal treatment after
diagnosis, can be contained with modern antibiotic treat-
ment for a few years, it will eventually result in a more rapid
decline in pulmonary function during adolescence or early
adult life. Unfortunately, the results of delayed diagnosis
and suboptimal treatment in the paediatric clinic may be
more easily identified by the CF physician and his team at
the adult clinic and may not always be apparent to the
paediatric team. This is a good reason for the paediatric and
adult CF staff to share their experience and even their staffs
to some extent as occurs in some centers [20].6. A communication and information revolution
It is essential that all who are responsible for CF care are
familiar with the well-established and latest advances in
treatment; but even in this age of information technology
this is not always easy. The past 20 years has seen an
explosive increase in the available information relating to
cystic fibrosis. Medline citations increased from almost
5000 in the decade between 1986 and 1995 to nearly 10,000
between 1996 and 2004. Also between 1966 and 1997 therewas a 30-fold increase in clinical trials relating to CF of
which over a third were only reported at meetings [21]. So
the previous legitimate complaint that there were too few
clinical trials in CF and that much of the treatment is based
largely on anecdotal experience is no longer true. The more
stringent review of the published work on CF by the
Cochrane Cystic Fibrosis and Genetics Disorders Group has
been a welcome advance but cannot cover all aspects of CF
care particularly relating to some of the practical but vitally
important details of everyday management [22]. An over-
whelming amount of scientific and quasi-scientific material
and advice, much of dubious quality, is generally available
on the Internet [23].7. Delay in implementing new information
Unfortunately, despite all this information there is still a
considerable delay in important advances influencing the
treatment of some patients. It has been suggested that there
may be too many sources of evidence, compiled with a
variable mix of scientific rigour and opinion, resulting in
confusing messages [24]. Even when evidence is deemed to
support an intervention, current health policy may prevent
clinicians from providing it. It is certainly true that an
increasingly important factor in the delivery of optimal care
is the ability of the providers to fund the increasingly
expensive drugs and this varies between CF centers and
countries.
So although the main principles of treatment are readily
available to those treating people with CF, it appears to be
the fine details of management, which may differ between
centers that account for some of the differences in the
condition of their patients.8. Marked differences in condition of people with CF at
different centers
Despite the wealth of information on the treatment of CF
it is very obvious both from clinical experience and the data
from CF Registries, that there were in the past, and continue
to be, striking differences in the condition of people
attending different CF Centers [25–27]. These differences
are far more marked than can be accounted for by climate,
socio-economic circumstances, age of diagnosis or variation
in prevalent gene mutations. The unpublished study of
Wood and Piazza [28] reflected very marked differences in
care and outcomes throughout the seventies at three
recognised US CF Centers where median survivals ranged
from 9.5, 18.1 to 22.8 years. Analysis showed differences
reflecting the closeness of supervision (number of clinic
visits) and intensity of treatment (days of intravenous
antibiotics) the patients received.
The superiority of CF center care over care in general
paediatric clinics was reflected in significantly better
Editorial 3survival in Victoria, Australia where CF center care was
already well-established, than in England and Wales [9].
More recently, surprisingly large differences were observed
between centers ranked within the upper and lower quartile
values for respiratory function and nutritional status. bThe
results suggested that the centers reporting higher values
for FEV1 and weight for age monitored patients more
frequently, reviewed spirometry more often and treated
patients more aggressivelyQ [29]. It has been observed that
the 10% difference in predicted FEV1%, seen between
centers, is of the same order as achieved by new treatments,
which are considered to show a significant benefit for
patients.
It is important that busy CF teams, although at times
reluctant to submit data, appreciate that patient registries are
absolutely essential to identify these significant differences
in clinical state and outcomes.9. Some treatment differences are ba matter of degree
rather than kindQ
What are the differences in management that seem to be
so important? Unfortunately many of the bfine detailsQ of
management have not been subjected to clinical trials. In
1958, a young paediatrician in Cleveland, Dr LeRoy
Matthews, was charged with planning and initiating a
bcomprehensive and prophylactic (preventive) treatment
programmeQ for the treatment of cystic fibrosis [30]. The
programme subsequently incorporated many of the compo-
nents now regarded as essential for modern CF center care
e.g. early correct diagnosis, a comprehensive programme to
deal with all the aspects of the disease and data collection to
validate the impact of the treatment on morbidity and
survival [5,6,31].
In 1960, Dr Terrence Gillespie, the CF Center Director
from Halifax, Nova Scotia reflected on why the results were
so much better in LeRoy Mathews’s CF center in Cleveland
than in Halifax, Nova Scotia as both clinics prescribed
similar treatment. After he had worked in both places he
concluded, bthe fundamental difference (in the treatment)
was a matter of degree rather than kind. Dr Matthews had
developed the concept of starting full treatment on the day
of diagnosis on every patient, regardless of the clinical
conditionQ [32]. This seems to be the most likely explan-
ation for these persisting differences, which still remain a
major cause for continuing concern.10. An bepidemicQ of standards, protocols and guidelines
In an attempt to ensure that patients are receiving the
most appropriate and acceptable treatment, various national
committees and working parties and many CF centers have
developed their own standards for general care and also
more detailed guidelines for various aspects of treatment[33–38]. Guidelines are defined as bsystematically devel-
oped statements to assist practitioner and patient decisions
about appropriate health care for specific clinical circum-
stancesQ [39]. Guidelines should be developed and endorsed
by the relevant professional bodies, be based on good
evidence of effectiveness, practicable and affordable, multi-
disciplinary where appropriate and always taking account of
patients’ choices and wishes.
Both guidelines, and the standards it is intended they
should achieve, are usually produced by consensus groups
of professionals, widely experienced in dealing with various
aspects of cystic fibrosis. They provide guidance for those
with less experience and also ensure the team members give
consistent advice to patients and carers.
Unfortunately the literature on guidelines in general can
be overpowering to the clinician who sees them as a tool for
making care more consistent and efficient and for closing
the gap between what clinicians do and what scientific
evidence supports [40]. The importance of the correct
development of guidelines has been stressed and there is
now extensive published work on the many aspects of
guidelines development—summarised clearly in the Guide-
lines Finder section of the National Electronic Library for
Health (http://libraries.nelh.nhs.uk). The inclusion of
parents and patients as user-representatives on consensus
groups is welcome and now routine in many countries. Also
the standards and guidelines should be available to all
patients and parents to reassure them they are receiving the
most appropriate treatment and to reduce the need for their
consulting less reliable sources.
However, not all are impressed by the recent epidemic of
advice observing—bWhat passes today for the standards of
clinical care — thousands of practice guidelines, often
conflicting, sometimes disreputable, always a mixture of
opinions and biases and, sometimes, evidence — is a messQ
[41].
It is has been suggested that it would be preferable to
start with what we know for certain, rather than producing
an indigestible survey of every article available and that the
bpurveyors of systematic reviews can begin to reverse this
trend by promoting practice recommendations instead: a
frequently updated compendium of all (and only) those
clinical practices whose evidence of benefit is undisputed
with the result that many health care professionals, goaded
by unimpeachable evidence, will try harder to translate it
into practiceQ [41]. Such advice has much to commend it.11. ECFS consensus on standards of care for people with
cystic fibrosis
In March 2004 Prof. Gerd Doering arranged a 2-day
European CF Society consensus meeting on Standards of
Care for People with Cystic Fibrosis. The final consensus
document is published in the present issue [42]. The 34
members of the consensus group were from most European
Editorial4countries and two from N. America; they represented the
many disciplines involved in CF care. The group met for 2
days in Artimino to agree standards of care and also to
answer some commonly asked and highly relevant ques-
tions. Some indication of the strength of evidence was given
to the answers. The facilities and functions of a CF center
were discussed also the staff required. The routines of CF
care were agreed including outpatients, inpatients, annual
reviews, details of various aspects of care, including the
newly diagnosed patient, the patient diagnosed in adult life
and atypical patients. The importance and role of other
specialists in CF care were detailed. The document finishes
with the 35 practical questions the answers to which were
agreed by the consensus group (some after considerable, at
times heated, discussion!).
The ECFS consensus group has achieved their aim of
defining standards for the routine evaluation, monitoring
and treatment of people with CF in Europe which, if
adopted by all centers, will provide a quality assurance
instrument and a basis for audit of CF care.12. Major efforts towards bbest careQ for all
It is general experience that the anticipated benefits of
guidelines are rarely fully realised in an everyday setting
and this is reflected in the variations in the outcome of the
patients. The variability in outlook is marked and the
median age of death in the US CF centers varies from 28.2
years in the bbestQ centers to 23.2 years for the rest [43].
Future research, using the CFF encounter-based database,
Port CF, will concentrate on improving care in three areas—
growth and nutrition, pulmonary maintenance and exacer-
bations and CF related diabetes [44].
There were a considerable number of studies reported at
the 2004 North American CF Conference aimed at improv-
ing the nutritional status [45] and other aspects of care of
patients in the poorly performing centers [46–48].
Schechter describes several key strategies for improving
care including appreciating the system must be changed,
working with an appropriate model of a system of clinical
care, making small sequential changes then spreading the
effective ones, using data to obtain feedback on effective-
ness and collaboration and stealing good ideas from others
[49].
Delivering suboptimal care to people with CF will
undoubtedly reduce their life span, in fact the CF
Foundation believes that improving the care of all people
with CF to that of the best centers would increase the life
expectancy by 7 years.13. Conclusions
The outlook for people with CF has improved remark-
ably due to more effective treatment developed at CFcenters. But the treatment regimens are increasingly com-
plex and the results achieved vary significantly between
centers as revealed by CF registries. It is unacceptable that
some people with CF are still receiving suboptimal treat-
ment, which will compromise their quality of life and
survival. This is the present unsatisfactory situation despite
the availability of numerous guidelines and a wealth of other
information. However, it is encouraging and timely that the
eventual recognition and acceptance of the marked varia-
bility in care, condition and outlook of people with CF has
now provided a stimulus to investigate the reasons and has
initiated an attempt to bring the standards of the bbestQ to all
centers.
The latest ECFS consensus document sets out the
standards to which all centers should be aiming and
which it is hoped all European centers will adopt. The
European CF Registry or its equivalent will be required
to ensure that care and outcomes achieved by all centers
are as good as those of the best centers. The current
emphasis on improving care is an important initiative,
which should have a major favourable influence on the
quality and duration of life of many people with cystic
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